Get the Daily Brief
Latest Biotech News
Clinical Trial Activity and Financing in Asia-Pacific Biopharma
The Asia-Pacific biopharma sector remains active with extensive financing, regulatory approvals, and clinical progress. Companies such as Daiichi Sankyo and Immuto have secured funding rounds,...
Scientific Integrity and Research Fraud Exposed
A significant incident of academic fraud was uncovered involving a physics professor in Iraq who orchestrated a publishing scam that exploited researchers for financial gain. The scheme involved...
Next-Gen Diagnostic Technologies and Omics Integration
Innovative diagnostic approaches employing multi-omics and AI are transforming disease detection and monitoring. Dana-Farber revealed MARLIN, a methylation plus AI-based tool that rapidly subtypes...
Pfizer's $7.3B Metsera Acquisition Reshapes Obesity Drug Race
Pfizer has agreed to acquire Metsera for up to $7.3 billion, marking a strategic return to the obesity and metabolic drug market following internal clinical setbacks earlier in 2025. The deal...
Merck’s Keytruda Qlex Gets FDA Nod for Rapid Subcutaneous Cancer Treatment
Merck & Co. has received FDA approval for Keytruda Qlex, the first subcutaneous (SC) administered immune checkpoint inhibitor that can be injected in approximately one minute, a significant...
FDA Accelerates Rare Disease Drug Approval for Barth Syndrome
Stealth BioTherapeutics secured accelerated FDA approval for elamipretide (Forzinity), a treatment for Barth syndrome, an ultra-rare pediatric mitochondrial cardioskeletal disorder. After an...
Ionis Achieves Phase 3 Success for Alexander Disease Antisense Therapy
Ionis Pharmaceuticals announced positive pivotal trial results for zilganersen, its antisense oligonucleotide therapy targeting Alexander disease, a rare neurodegenerative disorder. The phase 3...
AI Augmented Cancer Diagnostics and Imaging Innovations
Advances in artificial intelligence and molecular imaging technology are rapidly transforming oncology diagnostics. Researchers have developed an AI-driven diagnostic tool at Dana-Farber Cancer...
Legal Battle Intensifies Between Element Biosciences and Illumina
Element Biosciences filed multiple lawsuits against Illumina alleging anticompetitive conduct and patent infringement involving next-generation sequencing technologies. The complaints detail...
Breakthroughs in Cancer Research: Natural and Synthetic Therapeutics
Recent studies illuminate promising cancer therapies including an ethanolic extract from marine diatom Chaetoceros socialis inducing apoptosis in prostate and glioblastoma cells, and...
AI Integration Across Biotech and Clinical Trial Optimization
Artificial intelligence continues deep integration into biotech workflows and clinical research. Advarra launched an AI and data-driven protocol optimization tool, Study Design, leveraging...
Clinical and Diagnostic Advances in Metabolic and Rare Diseases
Progress in metabolic and rare disease therapeutics is marked by several clinical updates. MBX Biosciences announced positive phase II data for canvuparatide in chronic hypoparathyroidism,...
Stem Cell and Neurotechnology Insights for Disease Modeling and Treatment
Innovative research in stem cell-derived models and neurotechnology advances understanding and treatment of neurological disorders. Johns Hopkins University demonstrated AI-enabled detection of...
Pfizer’s Big Bet: $7.3B Metsera Acquisition Reinforces Obesity Pipeline
Pfizer has made a major move to re-enter the obesity drug market by agreeing to acquire Metsera for up to $7.3 billion, including contingencies based on clinical and regulatory milestones....
FDA Nod for Merck’s Keytruda SC Marks Faster Cancer Immunotherapy Delivery
The U.S. FDA has approved Merck's Keytruda Qlex, the first subcutaneous injection formulation of its blockbuster anti-PD-1 immunotherapy. This new product enables administration in about a minute...
Ionis’ Alexander Disease Drug Zilganersen Hits Pivotal Trial Endpoint
Ionis Pharmaceuticals reported positive pivotal Phase 3 trial results for zilganersen, an antisense oligonucleotide aimed at treating Alexander disease, a rare neurogenetic disorder. The drug...
AI-Driven Advances in Biotech: From Problematic Journal Detection to Clinical Trial Optimization
Artificial intelligence applications continue to expand in biotech, addressing challenges from open-access publishing to clinical research design. Researchers developed an AI platform capable of...
MapLight Therapeutics Plans IPO to Fund Neurological Drug Pipeline
MapLight Therapeutics, a biotech focused on neurological diseases, has filed for an initial public offering to list on Nasdaq under 'MPLT.' The company is advancing its lead drug candidate...
Stealth Biotherapeutics’ Barth Syndrome Drug Gains FDA Approval After Initial Setbacks
Stealth Biotherapeutics received FDA accelerated approval for its drug elamipretide (Forzinity) to improve muscle strength in patients with Barth syndrome, a rare pediatric mitochondrial disease....
Cancer Biotech MBX Biosciences Surges on Positive Phase II Data
MBX Biosciences announced positive top-line Phase II study results for canvuparatide in treating chronic hypoparathyroidism, achieving the trial’s primary endpoint. The drug demonstrated...